Masterhead

Thank you for visiting foster-city.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Gilead Announces Findings from New Preclinical Study Evaluating Novel Class of HIV Capsid Inhibitors

Published Monday February 27

SEATTLE–(BUSINESS Mon Feb 13 Gilead Sciences, Incorporated (NASDAQ:GILD) today announced findings from a preclinical study evaluating HIV capsid inhibitors (CAIs) for potential use as a long-acting antiretroviral (ARV) treatment.

The study identified novel HIV-1 capsid inhibitors with highly potent antiviral activity and a favorable resistance profile to existing ARVs in vitro. The data are being presented in an oral session at the 2017 Conference on Retroviruses and Opportunistic Infections in Seattle.

GS-CA1 is an investigational therapy and has not been determined to be safe or efficacious.

Article length: About 620 words.
Tags: Foster City
Read more at Drugs

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b